From:  Practical implications of androgen receptor inhibitors for prostate cancer treatment

Main trials including ARIs for PC treatment

DrugPatient stageStudyBenefit
EnzalutamidemCRPCa post-CTAFFIRM
2012		+ OS
EnzalutamidemCRPCa before-CTPREVAIL
2014		+ PFS
EnzalutamidemHSPCaENZAMET
2019		+ OS
EnzalutamidemHSPCaARCHES
2019		+ OS
EnzalutamidenmCRPCa, PSADT ≤ 10 msPROSPER
2018		+ OS
EnzalutamidenmHSPCa, PSADT ≤ 9 msEMBARK
2020		+ MFS
ApalutamidenmCRPCa, PSADT ≤ 10 msSPARTAN
2018		+ MFS
ApalutamidemHSPCaTITAN
2019		+ OS
DarolutamidenmCRPCa, PSADT ≤ 10 msARAMIS
2019		+ OS
DarolutamidemHSPCARASENS
2022		+ OS
Return to article view

CT: computed tomography; +: increasing benefit; mHSPC: metastatic hormone sensitive prostate cancer